Microsatellite Instability testing (MSI) [Tissue]
Microsatellite Instability testing testing (FFPE).
Oncogene panel testing [Tissue]
This EQA scheme is offered to help laboratories using high through put technologies (e.g., NGS, MassArray etc.) to accurately validate assay sensitivity and specificity. For specific tumour types, please register for the relevant scheme (e.g., Lung, Melanoma, Colorectal, Ovarian, Breast, Prostate, Pancreas). High quality reference materials are provided covering a range of genes with variants with ddPCR quantified allelic frequencies.
Ovarian, Breast, Prostate and Pancreatic Cancers (PARPi) [DNA, Germline]
BRCA1 and BRCA2 testing for Ovarian, Breast, prostate and pancreatic cancer (Germline DNA) in the context of PARP inhibitor prescription. This EQA is sponsored.
Prostate cancer (PARPi) [Plasma, cfDNA]
BRCA1 and BRCA2 testing in cfDNA (plasma) for Prostate Cancer in the context of PARP inhibitor prescription. This EQA is sponsored.
Ovarian and Prostate Cancer (PARPi) [Tissue, Somatic]
BRCA1, BRCA2 and HRR testing for Ovarian and Prostate cancer in the context of PARP inhibitor prescription (FFPE). This EQA is sponsored.
Lung Cancer (NSCLC) [Plasma]
EGFR, BRAF and KRAS testing of cfDNA (plasma) for NSCLC. This EQA is sponsored.